New developments in the treatment of drug-resistant tuberculosis: Clinical utility of bedaquiline and delamanid

Infection and Drug Resistance

Volumn 8, Issue , 2015, Pages 367-378

  Brigden, Grania ^a   Hewison, Cathy ^a   Varaine, Francis ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

Group 5 drugs; MDR TB; Tuberculosis drugs; XDR TB

Indexed keywords

BEDAQUILINE; CILASTATIN PLUS IMIPENEM; CLOFAZIMINE; DELAMANID; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PRETOMANID; PYRAZINAMIDE;

BLOOD TOXICITY; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG HALF LIFE; DRUG INHIBITION; DRUG REPOSITIONING; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; EVIDENCE BASED PRACTICE; GASTROINTESTINAL SYMPTOM; HEALTH CARE ACCESS; HUMAN; INJECTION SITE REACTION; LIVER TOXICITY; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; QT PROLONGATION; REVIEW; RISK BENEFIT ANALYSIS; SKIN DISCOLORATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

EID: 84946551645     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S68351     Document Type: Review

References (63)

1. World Health Organisation. Global Tuberculosis Report 2014. Geneva, Switzerland: World Health Organization; 2014. Available from: http://www.who.int/tb/publications/global_report/en/. Accessed July 11, 2015.
2. World Health Organisation. Towards Universal Access to Diagnosis and Treatment of Multidrug-resistant and Extensively Drug-resistant Tuberculosis by 2015: WHO Progress Report 2011. Geneva, Switzerland: World Health Organization; 2011.
3. World Health Organisation. Global Tuberculosis Report, Supplement Drug Resistant TB, Surveillance and Response. Geneva, Switzerland: World Health Organization; 2014. doi: WHO/HQ/TB/2014.12.
4. World Health Organisation. WHO End TB Strategy. Geneva: World Health Organization. Available from: http://www.who.int/tb/post2015_strategy/en/. Accessed July 11, 2015.
5. European Medicines Agency C for MP for HU. European Medicines Agency: Assessment Report: Deltyba. London, England: European Medicines Agency C for MP for HU; 2013. Procedure No EMEA/H/C/002552. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002552/smops/Positive/human_smop_000572.jsp&mid=WC0b01ac058001d127. Accessed July 11, 2015.
6. European Medicine Agency. Situro. London, England: European Medicine Agency. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/12/news_detail_001999.jsp&mid=WC0b01ac058004d5c1.
7. Food and Drug Administration. Sirturo (bedaquiline) Product Insert. Silver Spring, MD: Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf. Accessed July 11, 2015.
8. Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis. 2013;207(9):1352-1358. doi:10.1093/infdis/jis460.
9. Padayatchi N. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study. J Antimicrob Chemother. 2014;69(11):3103-3107. doi:101093/jac/dku235.
10. Gopal M, Padayatchi N, Metcalfe JZ, O’Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2013;17(8):1001-1007. doi:10.5588/ijtld.12.0144.
11. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151-2160. doi:10.1056/NEJMoa1112433.
12. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013;41(6):1393-1400. doi:10.1183/09031936.00125812.
13. Szumowski JD, Lynch JB. Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug Des Devel Ther. 2015;9:677-682. doi:10.2147/DDDT.S60923.
14. Otsuka Pharmaceutical Development and Commercialization, Inc. Safety and efficacy trial of delamanid for 6 months in patients with multidrug resistant tuberculosis (NCT01424670). Available from: https://clinicaltrials.gov/ct2/show/NCT01424670. Accessed July 11, 2015.
15. Matteelli A, Carvalho ACC, Dooley KE, et al. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010;5(6):849-858.
16. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline for the TMC207-C208 study group*. N Engl J Med. 2014;8371(21):723-732. doi:10.1056/NEJMoa1313865.
17. Treatment Action Group. HIV-HCV-TB Pipeline Report. New York, NY: Treatment Action Group; 2014.
18. Otsuka Pharmaceutical Development and Commercialization, Inc. A 6-month safety, efficacy, and pharmacokinetic trial of delamanid in pediatric patients with multidrug resistant tuberculosis (NCT01859923). Available from: http://clinicaltrials.gov/show/NCT01859923. Accessed July 11, 2015.
19. World Health Organisation. WHO interim guidance on the use of bedaquiline to treat MDR-TB. Geneva, Switzerland: World Health Organisation; 2013. Available from: http://www.who.int/mediacentre/news/notes/2013/bedaquiline_mdr_tb_20130613/en/. Accessed July 11, 2015.
20. World Health Organisation. The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis. Geneva, Switzerland: World Health Organisation; 2014. Available from: http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf?ua=1. Accessed July 11, 2015.
21. World Health Organisation. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva, Switzerland: World Health Organisation; 2014. Available from: http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809_eng.pdf?ua=1&ua=1. Accessed July 11, 2015.
22. World Health Organisation. World Health Organisation Prequalification.WH0 Prequalification. Geneva, Switzerland: World Health Organisation; 2012. Available from: http://apps.who.int/prequal/query/ProductRegistry.aspx?list=all. Accessed July 11, 2015.
23. Dey T, Brigden G, Cox H, Shubber Z, Cooke G, Ford N. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2013;68(2):284-293. doi:10.1093/jac/dks389.
24. Jagannath C, Reddy MV, Kailasam S, O’Sullivan JF, Gangadharam PR. Chemotherapeutic activity of clofazimine and its analogs against mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med. 1995;151(4):1083-1086.
25. Aung KJM, Van Deun A, Declercq E, et al. Successful “9-month Bangladesh regimen” for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014;18(10):1180-1187. doi:10.5588/ijtld.14.0100.
26. Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014;18(10):1188-1194. doi:10.5588/ijtld.13.0075.
27. Nunn AJ, Rusen I, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials. 2014;15:353. Available from: http://www.trialsjournal.com/content/15/1/353. Accessed July 11, 2015.
28. Diacon SM, Dawson R, Niekerk CV, et al. 14 Day EBA Study of PA-824 bedaquiline *pyrazinamide and clofazimine in smear positive TB patients. In: CROI; 2014; Boston, MA. Available from: http://www.croiconference.org/sessions/14-day-eba-study-pa-824-bedaquiline-pyrazinamide-and-clofazimine-smear-positive-tb-patients. Accessed July 11, 2015.
29. Grosset JH, Singer TG, Bishai WR, Grosset JH. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis. 2012;16(8):1005-1014. doi:10.5588/ijtld.12.0277.
30. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012;16(4):447-454. doi:10.5588/ijtld.11.0451.
31. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375(9728):1798-1807. doi:10.1016/S0140-6736(10)60492-8.
32. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367:1508-1518. Available from: http://www.nejm.org/doi/full/10.1056/NEJMoa1201964. Accessed July 11, 2015.
33. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother. 2005;49(7):2816-2821. doi:10.1128/AAC.49.7.2816-2821.2005.
34. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J. 2013; 41(6):1386-1392. doi:10.1183/09031936.00124312.
35. Médecins Sans Frontières Access Campaign. Ready set slow down. [Issue brief]. Available from: https://www.msfaccess.org/sites/default/files/MSF_assets/TB/Docs/MSF_IssueBrief_DRTB_ReadySet Slowdown.pdf. Accessed July 11, 2015.
36. Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis. 2015;60(2):188-194. doi:10.1093/cid/ciu786.
37. Ndjeka, N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis. 2015; 19(8):979-985.
38. Yeghiazaryan L. Armenian experience on treatment of XDR and pre-XDR patients with new drugs under compassionate use program. Presented at: Tuberculosis Symposium-Eastern Europe and Central Asia; February 17-18, 2015. Available at: http://www.tb-symposium.org/documents/en/presentations/Lusine_Yeghiazaryan_BDQ_practical_use_eng.pdf. Accessed July 11, 2015.
39. Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008;372(9647):1403-1409. doi:10.1016/S0140-6736 (08)61204-0.
40. Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 2014;383(9924):1230-1239. doi:10.1016/S0140-6736(13)62675-6.
41. Kurbatova EV, Taylor A, Gammino VM, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis. 2012;92(5):397-403.
42. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4(9):e6914. doi:10.1371/journal.pone.0006914.
43. Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med. 2006;144(9):650-659. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16670134. Accessed July 11, 2012.
44. O’Donnell MR, Padayatchi N, Kvasnovsky C, Werner L, Master I, Horsburgh CR. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis. 2013;19(3):416-424. doi:10.3201/eid1903.120998.
45. Bonnet M. Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis. Presented at: European Respiratory Society Annual Congress, 2013. Available from: http://erj.ersjournals.com/content/42/Suppl_57/190.short. Accessed July 11, 2015.
46. Brigden G, Nyang ’wa B-T, Du Cros P, et al. Policy and practice principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Heal Organ. 2014;92:68-74. doi:10.2471/BLT.13.122028.
47. Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40(6):1430-1442. doi:10.1183/09031936.00022912.
48. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2010;50(1):49-55. doi:10.1086/648675.
49. Jachym M. Bedaquiline: practical use and interim results in France. In: 4th Tuberculosis Symposium for Central Asia and Eastern Europe, Yerevan, Armenia; February 17-18, 2015.
50. Centre for Disease Control U. Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis, 2013. Available from: http://www.cdc.gov/mmwr/cme/conted.html. Accessed March 01, 2015.
51. Bedaquiline (Sirturo): Summary of Product Characteristics. European Medicines Agency. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002614/human_med_001730.jsp&mid=WC0b01ac058001d124. Accessed March 01, 2015.
52. World Health Organisation. Introduction of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis at Country Level: Implementation Plan. Geneva, Switzerland: World Health Organization; 2015. Available from: http://www.who.int/tb/publications/WHO_BDQimplementationplan.pdf. Accessed July 11, 2015.
53. ERS/WHO Tuberculosis Consilium [homepage on the Internet]. Available from: https://www.tbconsilium.org/. Accessed July 11, 2015.
54. Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology. 2011;120(22):103-110.
55. Shimokawa Y, Sasahara K, Yoda N, Mizuno K, Umehara K. Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro. Biol Pharm Bull. 2014;37(11):1727-1735.
56. Paccaly AJ, Petersen C, Patil S, et al. Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects. In: 19th International AIDS Conference; 2012; Washington, DC.
57. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of mmpl5 in mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58(5):2979-2981. doi:10.1128/AAC.00037-14
58. Somoskovi A. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir Soc J. 2015;45(2):554-557.
59. Global Drug Facility. GDF Impact on SLD Dynamics: 2011 vs 2013 Treatment Cost Comparison. Presentation, 2014. Available at: http://www.stoptb.org/assets/documents/gdf/whatis/SecondLineDrugs.pdf. Accessed July 11, 2015.
60. Médecins Sans Frontières. Under the Microscope. 3rd ed. Paris, France: Médecins Sans Frontières; 2013.
61. USAID. USAID and Johnson & Johnson to tackle antibiotic resistant TB. Available from: http://www.usaid.gov/news-information/press-releases/dec-11-2014-usaid-and-johnson-johnson-tackle-antibiotic-resistant-tuberculosis. Accessed July 11, 2015.
62. Tuberculosis (TB). An initiative to extend access to a new TB drug. World Health Organization. Available from: http://www.who.int/tb/features_archive/otsuka_2015/en/. Accessed July 11, 2015.
63. RESIST-TB. DR-TB Clinical Trial Progress Report. Updated May 2015. Available from: http://www.resisttb.org/?page_id=1602. Accessed July 11, 2015.